Pure Global
NCT06295536

Optimization of a Photoretinoscopy Method for Determining the Objective Refraction of Children

Optimization of a Photoretinoscopy Method for Determining the Objective Refraction of Children With a Smartphone/add-on Device in Hong-Kong
Essilor International·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ametropia
Drug/Device/Intervention
Comparator device, Closed-field autorefractometer
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Essilor International
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Aug 01, 2024
Enrollment
115 participants
Primary outcome

Objective refractive error

Summary

The objective is to compare the refractive parameters of the photorefraction prototype device
 without cycloplegia with the refractive parameters of reference device, an autorefractometer
 with and without cycloplegia.

ICD-10 classifications
Amblyopia ex anopsiaAmoebiasisAmoebiasis, unspecifiedMyoclonusOesophagitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06295536
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06295536 through Pure Global AI's free database. This phase not specified trial is sponsored by Essilor International and is currently Not yet recruiting. The study focuses on Ametropia. Target enrollment is 115 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.